What the peptide doctors are actually selling.

The ten largest peptide channels on YouTube are not media businesses. They are patient acquisition businesses that happen to produce video, and once you see the difference, almost everything said on them becomes legible.

Call the combined audience 1.2 million subscribers. That is an order of magnitude rather than an audited figure: counts move weekly, none are independently verified, and the channels overlap heavily in who watches them. The number is not the point. What sits behind it is.

I think the most common error in writing about this world is treating it as an influencer story, where the only question worth asking is whether a given physician is honest or a grifter. That framing produces accusations and very little understanding. The more useful question is structural: where does the money actually enter, and what does the structure reward? Follow that, and the answer is unambiguous. The video is the cheapest patient acquisition channel ever built, and everything downstream of it is the real business.

The ad revenue is a rounding error

Start with the number everyone assumes is the business. Health and medical content on YouTube earns roughly $6 to $18 in RPM, revenue per thousand views, well below the $28 to $40 that US finance channels command. The gap is not an accident: the Partner Program applies stricter monetization filters to health content, and pharmaceutical, device and supplement advertising is restricted differently in every market.

So a channel having a genuinely strong month, a million US views, grosses somewhere between $6,000 and $18,000 before production costs. For a physician, that is not nothing. It is also not a business.

Now run the arithmetic in the other direction. Patient acquisition in medical categories costs between $150 and $800 per lead when you buy it. If a channel with a million monthly views converts one viewer in a thousand into a consultation request, that is a thousand leads, or between $150,000 and $800,000 of acquisition value delivered in a month by content that also paid for itself.

That single ratio explains the format. It explains why the videos run long, why they read as lectures rather than entertainment, why the thumbnails promise a mechanism instead of a spectacle, and why the last ninety seconds so reliably turn toward something the viewer can do next. A channel optimized for ad revenue maximizes watch minutes. A channel optimized for the back end maximizes qualified intent, which is a different thing and produces different video.

The dispensary is the quietest line item

The revenue stack has an obvious tier and a quiet one. The obvious tier is clinical: consultations, memberships, follow-ups, labs. The quiet tier is the practitioner supplement dispensary, and it is the line least discussed and easiest to miss.

The mechanics are public. On Fullscript, the largest of these platforms, US practitioner accounts cap at a 35% discount off retail, and the operator chooses how to split it. Set the patient discount at 20% and the practice keeps a 15% margin. Drop the patient discount to 15% and the margin rises to 20%, immediately. New accounts start at no-profit, with patients simply getting 10% off, until the practitioner switches on payouts.

Note what that line requires: no inventory, no shipping, no prescription, no state licensure map, no controlled substance handling, no pharmacy relationship. It is the only revenue line in the entire stack that pays without a clinical encounter of any kind.

Which is, I think, the most underrated structural fact in this whole category. A video whose subject is a prescription-gated or legally unsettled compound very often lands on a recommendation the viewer can act on today, from a catalogue the presenter earns a documented percentage of. The subject of the video is the thing you cannot buy. The conversion is the thing you can.

Certification is the second-order business

The part of this economy that gets almost no press is the one selling to clinicians rather than to patients.

The training market is mature and priced accordingly. A fellowship in anti-aging and metabolic medicine runs five modules; the advanced version runs eight. Across the market, tuition ranges from roughly $699 for a single standalone course to about $18,000 for a full advanced fellowship, with $500 to $1,500 in certifying-body exam fees on top and annual dues of $200 to $600. Conferences sit alongside it, with their own registration, exhibitor and sponsorship economics.

Here is why that tier matters more than its revenue. Every physician who completes a certification becomes three things in sequence: a paying customer, then a referral node, then a peer who independently legitimizes the category. The audience for these videos is not only prospective patients. Part of it is prospective practitioners, and that part converts at a far higher price point.

A media business that sells its audience to advertisers has one customer. This structure has four, layered: the viewer becomes a patient, the patient becomes a member, the member becomes a supplement buyer, and a small slice of the audience becomes a franchisee of the idea itself. That is not an influencer model. It is closer to a distribution model with a content marketing front end.

The July vote became a marketing asset, not a legal one

On 23 and 24 July 2026, the Pharmacy Compounding Advisory Committee voted in favour of adding BPC-157, KPV, TB-500, MOTS-c, Epitalon and Semax to the 503A Bulks List, and against emideltide. BPC-157, KPV and TB-500 passed 8 to 6 with one abstention. MOTS-c passed 7 to 5 with two abstentions. FDA's own scientists opposed.

What happened next is the cleanest illustration of the incentive structure I can point to. The FDA is not bound by an advisory committee recommendation. Formal rulemaking is required, and HHS still has to act. None of those compounds became legally compoundable on the strength of that vote.

But "the advisory committee voted in favour" is a true sentence. It is compliant, it is checkable, and in a thirty-second video segment it does work that the underlying legal reality does not support. The vote did not change what is lawful. It changed what can be said confidently on camera, which in an acquisition business is the more valuable of the two.

That gap is the thing worth holding onto: the distance between a sentence that is technically accurate and an impression that is materially wrong is exactly the space this category operates in. It is not primarily created by dishonesty. It is created by the fact that the video is a storefront.

The strongest case against my own argument

Vertical integration is ordinary in medicine. Dermatologists sell skincare from the front desk. Dentists sell whitening. Orthodontists sell retainers at a markup. Nobody writes exposés about it, because the patient standing in the office can see that they are also standing in a shop.

Second, and more seriously: the mainstream system genuinely under-serves these questions. Someone who asks a primary care physician about BPC-157 will usually get a shrug, sometimes an accurate warning, rarely an engaged answer. Answering a question the system will not answer is not corruption. It is an unmet need, and unmet needs get filled by whoever shows up.

Third, many operators in this category do disclose. Affiliate relationships are named, sponsorships are tagged, clinic ownership is stated on the about page. And an audience, by itself, is not a conflict of interest.

All of that is fair, and it is why I am arguing about structure rather than character. But the disanalogy with the dermatology office is the whole ballgame. The patient at the front desk knows the room is a shop. The viewer at 11pm, three videos deep into a mechanism explainer delivered in a white coat in front of a bookshelf, is receiving a storefront in the visual grammar of a lecture. The revenue is disclosed in a line of text under a fold. The authority is transmitted in every frame.

What honest disclosure would actually require

The FTC's position is not ambiguous. A material connection, which includes payment, commission, free product or any relationship capable of affecting an endorsement's credibility, must be disclosed clearly and conspicuously, where the consumer encounters it before or at the moment of the endorsement. Brands are liable for the claims their endorsers make on their behalf. The commission has specifically pursued weight-loss products marketed as GLP-1 alternatives, and telehealth operators using unsubstantiated before-and-after imagery for peptide therapy.

Other regulators are moving as well. Between February and March 2026, the FDA issued warning letters to more than thirty telehealth companies over the marketing of compounded GLP-1 medications.

But sponsorship disclosure is the wrong standard here, because sponsorship is the smallest line in the stack. An honest disclosure for this category would name the architecture: whether the presenter owns or holds equity in a clinic treating the condition discussed, whether they operate a practitioner dispensary and at what margin, whether they sell training or certification in the subject matter, and whether any organization whose conferences they speak at is funded by manufacturers of the compounds under discussion. Four sentences. None of them are secrets. Almost none of them are said.

Until they are, the useful habit is not suspicion of the speaker. It is a question about the room: what is the next thing this video wants me to do, and who is paid when I do it? That is answerable from public information in nearly every case, and I think asking it is more protective than any amount of arguing about whether a given doctor is sincere. Most of them probably are. Sincerity and structure are independent variables, and only one of them is load-bearing.

Ozemback, September 2026